Nangibotide

Summary

Nangibotide is an investigational synthetic peptide that antagonises the triggering receptor expressed on myeloid cells‑1 (TREM‑1). Developed for acute inflammatory disorders, it is being evaluated chiefly in septic shock. By inhibiting TREM‑1‑driven amplification of the innate immune response, the drug aims to curb excessive inflammation, preserve vascular tone and improve organ function. Clinical development has progressed from first‑in‑human safety studies in healthy volunteers to phase 2 trials in septic‑shock patients, with ongoing work on biomarker‑guided patient selection.

Mechanism of Action

Nangibotide is a short peptide that binds to the extracellular domain of TREM‑1, a receptor on neutrophils and monocytes that amplifies innate immune signalling via the DAP12 adaptor. Activation of TREM‑1 triggers NF‑κB‑dependent production of pro‑inflammatory cytokines, chemokines and enhances endothelial permeability. By blocking this receptor, nangibotide dampens the downstream cytokine surge, reduces vascular leakage and supports endothelial function, thereby moderating the hyper‑inflammatory phase of sepsis and septic shock.

What the Research Shows

A first‑in‑human, randomised, double‑blind phase I study in 27 healthy volunteers demonstrated that nangibotide is safe, well tolerated and shows dose‑proportional pharmacokinetics with a short effective half‑life, supporting intravenous infusion. A phase 2a randomised trial in 49 septic‑shock patients reported no increase in treatment‑emergent adverse events versus placebo and exploratory trends toward greater SOFA score reduction and organ‑support benefit in patients with high baseline soluble TREM‑1 (sTREM‑1). The subsequent phase 2b ASTONISH trial randomised 355 septic‑shock patients to two infusion doses or placebo; the primary SOFA endpoint was not met and mortality differences were not statistically significant, although safety remained comparable to placebo. Review articles note that nangibotide is the only TREM‑1 inhibitor to reach clinical testing and highlight its potential in biomarker‑guided precision immunotherapy for sepsis.

Reported Benefits

Early clinical data consistently show a favourable safety and tolerability profile, with no serious drug‑related adverse events and no anti‑drug antibody formation. Pharmacokinetic studies indicate predictable exposure with intravenous infusion. In phase 2a, patients with elevated sTREM‑1 exhibited modest improvements in organ‑failure scores, suggesting that biomarker‑selected subgroups may derive benefit. These findings support the hypothesis that TREM‑1 blockade can attenuate harmful inflammation in septic shock.

Limitations of the Evidence

Definitive efficacy has not been demonstrated; the phase 2b ASTONISH trial failed to achieve its primary SOFA improvement endpoint and mortality differences were not statistically significant. Sample sizes remain modest and subgroup analyses (e.g., high sTREM‑1) are exploratory. Consequently, larger, adequately powered phase 3 trials are required to confirm clinical benefit and to establish optimal dosing and patient‑selection strategies.

Safety Considerations

Across phase I, phase 2a and phase 2b studies, nangibotide was associated with only mild adverse events, comparable in frequency to placebo. No serious drug‑related events, drug withdrawals, or anti‑drug antibodies were reported. The short half‑life and rapid clearance suggest limited systemic accumulation. While no specific safety signals have emerged, the investigational status warrants continued monitoring for unforeseen effects in larger trials.

How It Is Administered

Nangibotide is formulated for continuous intravenous infusion, typically preceded by a short loading dose. Phase I studies used single 15‑minute infusions followed by 7‑hour infusions; phase 2 trials employed continuous infusions at rates up to 3 mg·kg⁻¹·h⁻¹ for up to five days. The peptide is supplied as a sterile solution suitable for IV administration.

Routes of Administration

Goals & Uses

• SepsisInfectious DiseaseModerate
• Reduction of mortality in septic shockCritical Care / Anti InflammatoryModerate
• Septic ShockCritical CareModerate
• Attenuation of TREM-1-mediated hyperinflammationImmunomodulationModerate
• Organ dysfunction prevention in sepsisOrgan ProtectionModerate
• Biomarker-guided patient stratification in sepsisPrecision MedicineModerate
• Severe COVID‑19Viral InfectionLow

Contraindications

• Known hypersensitivity to nangibotide or excipientsAllergyHigh
• Known hypersensitivity to Nangibotide or any excipientsAllergyHigh
• Severe immunocompromised statesImmunologicalModerate

Adverse Effects

• Elevated liver enzymes (transient)HepaticRare
• HypotensionCardiovascularUncommonLow blood pressure
• Infusion site erythemaLocalCommon
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Infusion-related reactionsHypersensitivityUncommon

Drug Interactions

• Vasopressors (norepinephrine, vasopressin)Low
• CorticosteroidsModerate
• Concurrent high‑dose corticosteroidsModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric patientsAgeRelative
• Pediatrics (<12 years)AgeRelative
• Pregnant or lactating womenReproductiveRelative
• Patients with chronic autoimmune conditions on immunosuppressantsComorbidityRelative

Regulatory Status

• European UnionInvestigationalPhase 2 clinical program ongoing
• United StatesInvestigationalUnder IND for sepsis; not FDA‑approved
• United KingdomInvestigationalClinical trials authorized by MHRA

Not approved by any regulatory agency. Investigated under clinical trial frameworks in Europe and the US. Phase 2 trial (ASTONISH) conducted in septic shock patients. Orphan or fast-track designations not publicly confirmed as of last available data.

Evidence & Sources

• Recent advances of precision immunotherapy in sepsis
  Journal ArticleModerateArapis A, Panagiotopoulos D, Giamarellos-Bourboulis EJ2025-01-01T00:00:00.000000Z
• A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition
  Journal ArticleModerateCuvier V, et al.2018-01-01T00:00:00.000000Z
• Enhancing sepsis biomarker development: key considerations from public and private perspectives
  Journal ArticleModerateLlitjos JF, et al.2024-01-01T00:00:00.000000Z
• Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial
  Journal ArticleModerateFrançois B, et al.2020-01-01T00:00:00.000000Z
• Triggering receptor expressed on myeloid cells-1 in sepsis, and current insights into clinical studies
  Journal ArticleModerateTheobald V, et al.2024-01-01T00:00:00.000000Z
• Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial
  Journal ArticleModerateFrançois B, et al.2023-01-01T00:00:00.000000Z

Frequently Asked Questions